Natural anti-CCR5 antibodies in HIV-infection and -exposure

Journal of Translational Medicine

Volumn 9, Issue SUPPL. 1, 2010, Pages

  Lopalco, Lucia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTIBODY; HGS 004; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2D7; MONOCLONAL ANTIBODY MC 1; MONOCLONAL ANTIBODY MC 4; MONOCLONAL ANTIBODY MC 6; MONOCLONAL ANTIBODY PA14; MONOCLONAL ANTIBODY PA9; PRO 140; RECEPTOR ANTIBODY; ROAB12; ROAB14; ROAB18; UNCLASSIFIED DRUG; ANTIBODY; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ANTIVIRAL ACTIVITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; GENE MUTATION; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREGULATION; INNATE IMMUNITY; MOLECULAR DYNAMICS; MUCUS SECRETION; NONHUMAN; PASSIVE IMMUNIZATION; PROTECTION; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS ENTRY; VIRUS INHIBITION; AMINO ACID SEQUENCE; ANIMAL; BREAST MILK; CHEMISTRY; HAPLORHINI; IMMUNE SYSTEM; IMMUNOLOGY; MOLECULAR GENETICS; MOUSE; PROTEIN TERTIARY STRUCTURE; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIBODIES, ANTI-IDIOTYPIC; HAPLORHINI; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MILK, HUMAN; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CCR5;

EID: 79251504918     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-S1-S4     Document Type: Review

References (81)

1. Eslahpazir J, Jenabian MA, Bouhlal H, Hocini H, Carbonneil C, Gresenguet G, Keou FX, LeGoff J, Saidi H, Requena M, et al. Infection of macrophages and dendritic cells with primary R5-tropic human immunodeficiency virus type 1 inhibited by natural polyreactive anti-CCR5 antibodies purified from cervicovaginal secretions. Clin Vaccine Immunol 2008, 15:872-84. 10.1128/CVI.00463-07, 2394833, 18353923.
2. Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol 2008, 20:149-57. 10.1016/j.coi.2008.03.014, 2532490, 18434123.
3. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008, 112:1570-80. 10.1182/blood-2008-02-078071, 2518873, 18725575.
4. Quan CP, Berneman A, Pires R, Avrameas S, Bouvet JP. Natural polyreactive secretory immunoglobulin A autoantibodies as a possible barrier to infection in humans. Infect Immun 1997, 65:3997-4004. 175574, 9316998.
5. Esplin BL, Welner RS, Zhang Q, Borghesi LA, Kincade PW. A differentiation pathway for B1 cells in adult bone marrow. Proc Natl Acad Sci U S A 2009, 106:5773-8. 10.1073/pnas.0811632106, 2666989, 19307589.
6. Holodick NE, Repetny K, Zhong X, Rothstein TL. Adult BM generates CD5+ B1 cells containing abundant N-region additions. Eur J Immunol 2009, 39:2383-94. 10.1002/eji.200838920, 2792924, 19714574.
7. Duan B, Morel L. Role of B-1a cells in autoimmunity. Autoimmun Rev 2006, 5:403-8. 10.1016/j.autrev.2005.10.007, 16890894.
8. Racine R, Winslow GM. IgM in microbial infections: taken for granted?. Immunol Lett 2009, 125:79-85. 10.1016/j.imlet.2009.06.003, 2747358, 19539648.
9. Zhong X, Lau S, Bai C, Degauque N, Holodick NE, Steven SJ, Tumang J, Gao W, Rothstein TL. A novel subpopulation of B-1 cells is enriched with autoreactivity in normal and lupus-prone mice. Arthritis Rheum 2009, 60:3734-43. 10.1002/art.25015, 2868318, 19950285.
10. Whitmore AC, Neely HR, Diz R, Flood PM. Rapid induction of splenic and peritoneal B-1a cells in adult mice by thymus-independent type-2 antigen. J Immunol 2004, 173:5406-14.
11. Alugupalli KR, Leong JM, Woodland RT, Muramatsu M, Honjo T, Gerstein RM. B1b lymphocytes confer T cell-independent long-lasting immunity. Immunity 2004, 21:379-90. 10.1016/j.immuni.2004.06.019, 15357949.
12. Widhopf GF, Brinson DC, Kipps TJ, Tighe H. Transgenic expression of a human polyreactive Ig expressed in chronic lymphocytic leukemia generates memory-type B cells that respond to nonspecific immune activation. J Immunol 2004, 172:2092-9.
13. Hsu MC, Toellner KM, Vinuesa CG, Maclennan IC. B cell clones that sustain long-term plasmablast growth in T-independent extrafollicular antibody responses. Proc Natl Acad Sci U S A 2006, 103:5905-10. 10.1073/pnas.0601502103, 1424660, 16585532.
14. Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol 2008, 4:491-8. 10.1038/ncprheum0895, 2703183, 18756274.
15. Bouhlal H, Hocini H, Quillent-Gregoire C, Donkova V, Rose S, Amara A, Longhi R, Haeffner-Cavaillon N, Beretta A, Kaveri SV, et al. Antibodies to C-C chemokine receptor 5 in normal human IgG block infection of macrophages and lymphocytes with primary R5-tropic strains of HIV-1. J Immunol 2001, 166:7606-11.
16. Bouhlal H, Latry V, Requena M, Aubry S, Kaveri SV, Kazatchkine MD, Belec L, Hocini H. Natural antibodies to CCR5 from breast milk block infection of macrophages and dendritic cells with primary R5-tropic HIV-1. J Immunol 2005, 174:7202-9.
17. Kaminski DA, Stavnezer J. Enhanced IgA class switching in marginal zone and B1 B cells relative to follicular/B2 B cells. J Immunol 2006, 177:6025-9.
18. Chen C, Stenzel-Poore MP, Rittenberg MB. Natural auto- and polyreactive antibodies differing from antigen-induced antibodies in the H chain CDR3. J Immunol 1991, 147:2359-67.
19. Martin T, Crouzier R, Weber JC, Kipps TJ, Pasquali JL. Structure-function studies on a polyreactive (natural) autoantibody. Polyreactivity is dependent on somatically generated sequences in the third complementarity-determining region of the antibody heavy chain. J Immunol 1994, 152:5988-96.
20. Vassilev TL, Veleva KV. Natural polyreactive IgA and IgM autoantibodies in human colostrums. Scand J Immunol 1996, 44:535-9. 10.1046/j.1365-3083.1996.d01-333.x, 8947607.
21. Ditzel HJ, Rosenkilde MM, Garred P, Wang M, Koefoed K, Pedersen C, Burton DR, Schwartz TW. The CCR5 receptor acts as an alloantigen in CCR5Delta32 homozygous individuals: identification of chemokineand HIV-1-blocking human antibodies. Proc Natl Acad Sci U S A 1998, 95:5241-5. 10.1073/pnas.95.9.5241, 20245, 9560260.
22. Lopalco L, Barassi C, Pastori C, Longhi R, Burastero SE, Tambussi G, Mazzotta F, Lazzarin A, Clerici M, Siccardi AG. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J Immunol 2000, 164:3426-33.
23. Grene E, Pinto LA, Kwak-Kim JY, Giorgi JV, Landay AL, Kessler HA, Beer AE, Shearer GM. Increased levels of anti-CCR5 antibodies in sera from individuals immunized with allogeneic lymphocytes. Aids 2000, 14:2627-8. 10.1097/00002030-200011100-00035, 11101084.
24. Devito C, Broliden K, Kaul R, Svensson L, Johansen K, Kiama P, Kimani J, Lopalco L, Piconi S, Bwayo JJ, et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J Immunol 2000, 165:5170-6.
25. Devito C, Hinkula J, Kaul R, Lopalco L, Bwayo JJ, Plummer F, Clerici M, Broliden K. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. Aids 2000, 14:1917-20. 10.1097/00002030-200009080-00006, 10997395.
26. Blanpain C, Vanderwinden JM, Cihak J, Wittamer V, Le Poul E, Issafras H, Stangassinger M, Vassart G, Marullo S, Schlndorff D, et al. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell 2002, 13:723-37. 10.1091/mbc.01-03-0129, 65662, 11854425.
27. Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999, 73:4145-55. 104194, 10196311.
28. Grene E, Pinto LA, Landay AL, Kessler HA, Anderson SA, Dolan MJ, Shearer GM. Anti-CCR5 antibodies in sera of HIV-positive individuals. Hum Immunol 2001, 62:143-5. 10.1016/S0198-8859(00)00243-3, 11182224.
29. Barassi C, Lazzarin A, Lopalco L. CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. Blood 2004, 104:2205-6. 10.1182/blood-2004-06-2134, 15377578.
30. Pastori C, Weiser B, Barassi C, Uberti-Foppa C, Ghezzi S, Longhi R, Calori G, Burger H, Kemal K, Poli G, et al. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood 2006, 107:4825-33. 10.1182/blood-2005-06-2463, 1895813, 16522810.
31. Diomede L, Nyoka S, Scotti L, Parri A, Merati V, Pastori C, Longhi R, Zambon A, Sherman G, Sarzotti-Kelsoe M, Gray C, Lopalco L. Pattern of HIV-1-env binding and neutralizing antibodies in subtype C infected women and in their HIV-1-seronegative neonates. Submitted for publication 2010,
32. Lopalco L, Nguyen M, Bégaud E, Marecha V, Pancino G, Lazzarin L, Burastero S. The role of Cell- and HIV-specific antibodies in HIV-1 exposed seronegative cohorts from different genetic origin: comparison between European, Asian and African cohorts. In: AIDS Vaccine International Conference 2005, Montreal, Canada.
33. Bomsel M, Pastori C, Tudor D, Alberti C, Garcia S, Ferrari D, Lazzarin A, Lopalco L. Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. Aids 2007, 21:13-22. 10.1097/QAD.0b013e328011049b, 17148963.
34. Barassi C, Soprana E, Pastori C, Longhi R, Buratti E, Lillo F, Marenzi C, Lazzarin A, Siccardi AG, Lopalco L. Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy. J Virol 2005, 79:6848-58. 10.1128/JVI.79.11.6848-6858.2005, 1112124, 15890924.
35. Trkola A, Ketas TJ, Nagashima KA, Zhao L, Cilliers T, Morris L, Moore JP, Maddon PJ, Olson WC. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001, 75:579-88. 10.1128/JVI.75.2.579-588.2001, 113953, 11134270.
36. Olson WC, Jacobson JM. CCR5 monoclonal antibodies for HIV-1 therapy. Curr Opin HIV AIDS 2009, 4:104-11. 10.1097/COH.0b013e3283224015, 2760828, 19339948.
37. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 1999, 274:9617-26. 10.1074/jbc.274.14.9617, 10092648.
38. Zhang J, Rao E, Dioszegi M, Kondru R, DeRosier A, Chan E, Schwoerer S, Cammack N, Brandt M, Sankuratri S, et al. The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies. Antimicrob Agents Chemother 2007, 51:1386-97. 10.1128/AAC.01302-06, 1855447, 17242138.
39. Huber M, Olson WC, Trkola A. Antibodies for HIV treatment and prevention: window of opportunity?. Curr Top Microbiol Immunol 2008, 317:39-66. full_text, 17990789.
40. Ji C, Brandt M, Dioszegi M, Jekle A, Schwoerer S, Challand S, Zhang J, Chen Y, Zautke L, Achhammer G, et al. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. Antiviral Res 2007, 74:125-37. 10.1016/j.antiviral.2006.11.003, 17166600.
41. Spruth M, Stoiber H, Kacani L, Schonitzer D, Dierich MP. Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients. AIDS Res Hum Retroviruses 1999, 15:533-43. 10.1089/088922299311051, 10221530.
42. Peters B, Whittall T, Babaahmady K, Gray K, Vaughan R, Lehner T. Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection. Lancet 2004, 363:518-24. 10.1016/S0140-6736(04)15538-4, 14975614.
43. Lopalco L. Humoral Immunity in HIV-1 Exposure: Cause or Effect of HIV Resistance?. Current HIV Research 2004, 2:79-92. 10.2174/1570162043484951, 15053342.
44. Bourinbaiar AS, Metadilogkul O, Jirathitikal V. Mucosal AIDS vaccines. Viral Immunol 2003, 16:427-45. 10.1089/088282403771926274, 14733732.
45. Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc 2009, 109:S13-7.
46. Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu Rev Immunol 1997, 15:235-70. 10.1146/annurev.immunol.15.1.235, 9143688.
47. Turcanova VL, Bundgaard B, Hollsberg P. Human herpesvirus-6B induces expression of the human endogenous retrovirus K18-encoded superantigen. J Clin Virol 2009, 46:15-9. 10.1016/j.jcv.2009.05.015, 19505847.
48. Nellaker C, Yao Y, Jones-Brando L, Mallet F, Yolken RH, Karlsson H. Transactivation of elements in the human endogenous retrovirus W family by viral infection. Retrovirology 2006, 3:44. 10.1186/1742-4690-3-44, 1539011, 16822326.
49. Sutkowski N, Chen G, Calderon G, Huber BT. Epstein-Barr virus latent membrane protein LMP-2A is sufficient for transactivation of the human endogenous retrovirus HERV-K18 superantigen. J Virol 2004, 78:7852-60. 10.1128/JVI.78.14.7852-7860.2004, 434102, 15220463.
50. Ruprecht K, Obojes K, Wengel V, Gronen F, Kim KS, Perron H, Schneider-Schaulies J, Rieckmann P. Regulation of human endogenous retrovirus W protein expression by herpes simplex virus type 1: implications for multiple sclerosis. J Neurovirol 2006, 12:65-71. 10.1080/13550280600614973, 16595376.
51. Jern P, Coffin JM. Effects of retroviruses on host genome function. Annu Rev Genet 2008, 42:709-32. 10.1146/annurev.genet.42.110807.091501, 18694346.
52. Arnaud F, Caporale M, Varela M, Biek R, Chessa B, Alberti A, Golder M, Mura M, Zhang YP, Yu L, et al. A paradigm for virus-host coevolution: sequential counter-adaptations between endogenous and exogenous retroviruses. PLoS Pathog 2007, 3:e170. 10.1371/journal.ppat.0030170, 2065879, 17997604.
53. Russo S, Lopalco L. Is autoimmunity a component of natural immunity to HIV?. Curr HIV Res 2006, 4:177-90. 10.2174/157016206776055011, 16611056.
54. Wolinsky SM, Veazey RS, Kunstman KJ, Klasse PJ, Dufour J, Marozsan AJ, Springer MS, Moore JP. Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses. Virology 2004, 328:19-29. 10.1016/j.virol.2004.07.021, 15380354.
55. Corbeau P, Reynes J. CCR5 antagonism in HIV infection: ways, effects, and side effects. Aids 2009, 23:1931-43. 10.1097/QAD.0b013e32832e71cd, 19724192.
56. Jacobson JM, Saag MS, Thompson MA, Fischl MA, Liporace R, Reichman RC, Redfield RR, Fichtenbaum CJ, Zingman BS, Patel MC, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008, 198:1345-52. 10.1086/592169, 18771406.
57. Lalezari J, Yadavalli GK, Para M, Richmond G, Dejesus E, Brown SJ, Cai W, Chen C, Zhong J, Novello LA, et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis 2008, 197:721-7. 10.1086/527327, 18266604.
58. Aarons EJ, Beddows S, Willingham T, Wu L, Koup RA. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology 2001, 287:382-90. 10.1006/viro.2001.1046, 11531415.
59. Safarian D, Carnec X, Tsamis F, Kajumo F, Dragic T. An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. Virology 2006, 352:477-84. 10.1016/j.virol.2006.05.016, 16777164.
60. Chackerian B, Lowy DR, Schiller JT. Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A 1999, 96:2373-8. 10.1073/pnas.96.5.2373, 26791, 10051649.
61. Chackerian B, Briglio L, Albert PS, Lowy DR, Schiller JT. Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol 2004, 78:4037-47. 10.1128/JVI.78.8.4037-4047.2004, 374281, 15047820.
62. Chain BM, Noursadeghi M, Gardener M, Tsang J, Wright E. HIV blocking antibodies following immunisation with chimaeric peptides coding a short N-terminal sequence of the CCR5 receptor. Vaccine 2008, 26:5752-9. 10.1016/j.vaccine.2008.08.025, 2670972, 18765264.
63. Devito C, Zuber B, Schroder U, Benthin R, Okuda K, Broliden K, Wahren B, Hinkula J. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 2004, 173:7078-89.
64. Buratti E, McLain L, Tisminetzky S, Cleveland SM, Dimmock NJ, Baralle FE. The neutralizing antibody response against a conserved region of human immunodeficiency virus type 1 gp41 (amino acid residues 731-752) is uniquely directed against a conformational epitope. J Gen Virol 1998, 79(Pt 11):2709-16.
65. Pastori C, Clivio A, Diomede L, Consonni R, De Mori GM, Longhi R, Colombo G, Lopalco L. Two amino acid substitutions within the first external loop of CCR5 induce human immunodeficiency virus-blocking antibodies in mice and chickens. J Virol 2008, 82:4125-34. 10.1128/JVI.02232-07, 2293020, 18256149.
66. Bogers WM, Bergmeier LA, Ma J, Oostermeijer H, Wang Y, Kelly CG, Ten Haaft P, Singh M, Heeney JL, Lehner T. A novel HIV-CCR5 receptor vaccine strategy in the control of mucosal SIV/HIV infection. Aids 2004, 18:25-36. 10.1097/00002030-200401020-00003, 15090826.
67. Misumi S, Nakayama D, Kusaba M, Iiboshi T, Mukai R, Tachibana K, Nakasone T, Umeda M, Shibata H, Endo M, et al. Effects of immunization with CCR5-based cycloimmunogen on simian/HIVSF162P3 challenge. J Immunol 2006, 176:463-71.
68. Moore JP, Kuritzkes DR. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS 2009, 4:118-24. 10.1097/COH.0b013e3283223d46, 2896203, 19339950.
69. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359:1429-41. 10.1056/NEJMoa0803152, 18832244.
70. Pugach P, Ketas TJ, Michael E, Moore JP. Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology 2008, 377:401-7. 10.1016/j.virol.2008.04.032, 2528836, 18519143.
71. Gaertner H, Cerini F, Escola JM, Kuenzi G, Melotti A, Offord R, Rossitto-Borlat I, Nedellec R, Salkowitz J, Gorochov G, et al. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. Proc Natl Acad Sci U S A 2008, 105:17706-11. 10.1073/pnas.0805098105, 2584686, 19004761.
72. Fauci A. Pathogenesis of HIV disease: opportunities for new prevention interventions. Clinical Infectious Diseases 2007, 45:S206-S212. 10.1086/522540, 18190288.
73. Klasse PJ, Shattock R, Moore JP. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med 2008, 59:455-71. 10.1146/annurev.med.59.061206.112737, 17892435.
74. Quillent C, Oberlin E, Braun J, Rousset D, Gonzalez-Canali G, Metais P, Montagnier L, Virelizier JL, Arenzana-Seisdedos F, Beretta A. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998, 351:14-8. 10.1016/S0140-6736(97)09185-X, 9433423.
75. Paxton WA, Kang S. Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression. Semin Immunol 1998, 10:187-94. 10.1006/smim.1998.0132, 9653045.
76. Wu L, Paxton WA, Kassam N, Ruffing N, Rottman JB, Sullivan N, Choe H, Sodroski J, Newman W, Koup RA, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997, 185:1681-91. 10.1084/jem.185.9.1681, 2196298, 9151905.
77. Telenti A. Safety concerns about CCR5 as an antiviral target. Curr Opin HIV AIDS 2009, 4:131-5. 10.1097/COH.0b013e3283223d76, 19339952.
78. Wheeler J, McHale M, Jackson V, Penny M. Assessing theoretical risk and benefit suggested by genetic association studies of CCR5: experience in a drug development programme for maraviroc. Antivir Ther 2007, 12:233-45.
79. Schroder C, Pierson RN, Nguyen BN, Kawka DW, Peterson LB, Wu G, Zhang T, Springer MS, Siciliano SJ, Iliff S, et al. CCR5 blockade modulates inflammation and alloimmunity in primates. J Immunol 2007, 179:2289-99.
80. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008, 359:1442-55. 10.1056/NEJMoa0803154, 18832245.
81. Lopalco L, Barassi C, Paolucci C, Breda D, Brunelli D, Nguyen M, Nouhin J, Luong TT, Truong LX, Clerici M, et al. Predictive value of anti-cell and anti-human immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J Gen Virol 2005, 86:339-48. 10.1099/vir.0.80585-0, 15659753.